SCHEMBL754172

SCHEMBL754172

O=S(=O)(O)CCCCCCCOCCCCCCCS(=O)(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.46
LMNA P02545 4/20 0.38
BLM P54132 2/20 0.38
PTGS1 P23219 1/20 0.38
PDE4A P27815 1/20 0.38
SLC6A6 P31641 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 3/20 0.35
POLB P06746 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 2/20 0.35
ALOX15 P16050 2/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 1/20 0.35
BRCA1 P38398 1/20 0.35
GMNN O75496 1/20 0.35
PKM P14618 1/20 0.35
THPO P40225 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL754168 1.00 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL419968 1.00 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL420986 1.00 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL12977769 0.97 APP (0.44) APPLMNABLMPTGS1PDE4A
SCHEMBL16642006 0.97 APP (0.44) APPLMNABLMPTGS1PDE4A
SCHEMBL37545 0.97 APP (0.48) APPLMNABLMPTGS1PDE4A
Bromide SCHEMBL31659017 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL312671 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL30782568 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL30133577 0.95 APP (0.46) APPLMNABLMPTGS1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3100728-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CYDEX PHARMACEUTICALS INC (US) 2019-11-20 EP disclosed
US-10111863-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2018-10-30 US disclosed
US-20170007586-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2017-01-12 US disclosed
EP-3100728-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME Cydex Pharmaceuticals, Inc. (US) 2016-12-07 EP disclosed
US-9399067-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2016-07-26 US disclosed
EP-2429291-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CYDEX PHARMACEUTICALS INC (US) 2016-07-06 EP disclosed
US-20150005341-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-01-01 US disclosed
US-8835407-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2014-09-16 US disclosed
US-20130012534-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same CYDEX PHARMACEUTICALS, INC. 2013-01-10 US disclosed
US-8236782-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2012-08-07 US disclosed
EP-2429291-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CyDex Pharmaceuticals, Inc. (US) 2012-03-21 EP disclosed
WO-2010132711-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CYDEX PHARMACEUTICALS, INC. (US) 2010-11-18 WO disclosed
US-20100291056-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2010-11-18 US disclosed
US-7115586-B2 Non-inclusion cyclodextrin complexes DECODE GENETICS EHF. (IS) 2006-10-03 US disclosed
EP-1443969-A2 NON-INCLUSION CYCLODEXTRIN COMPLEXES Decode Genetics EHF (IS) 2004-08-11 EP disclosed
US-20030109492-A1 Non-inclusion cyclodextrin complexes DECODE GENETICS EHF. (IS) 2003-06-12 US disclosed
WO-2003033025-A2 CYCLODEXTRIN COMPLEXES DECODE GENETICS EHF (IS) 2003-04-24 WO disclosed
US-5472954-A Combining cyclodextrin with polymer before adding active material CYCLOPS H.F. (IS) 1995-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170007586-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME P2RY6, GP6, PFKP APP 867/4885LMNA 3458/4885BLM 1839/4885
US-20150005341-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME P2RY6, GP6, PFKP APP 867/4885LMNA 3458/4885BLM 1839/4885
US-20030109492-A1 Non-inclusion cyclodextrin complexes SI, CNDP2, NONO APP 330/4885LMNA 3359/4885BLM 3808/4885
US-20130012534-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same P2RY6, GP6, PFKP APP 867/4885LMNA 3458/4885BLM 1839/4885
US-10111863-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same P2RY6, GP6, PFKP APP 867/4885LMNA 3458/4885BLM 1839/4885
US-20100291056-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same P2RY6, GP6, PFKP APP 867/4885LMNA 3458/4885BLM 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.